11 results
To study whether the existing eGFR cut-off levels for preventive hydration of < 45 ml/min or between 45-60 ml/min in combination of other comorbidity at risk of CIN can be safely lowered to an eGFR < 30 ml/min, regarsless of the…
The results of this study will give better insights in the role of ADMA in the development of systemic endothelial dysfunction.
The main study parameter is the routine measurement of serum phosphate concentrations after 8 and 12 weeks. Other study parameters are compliance to phosphate binders and supplement-related complaints such as nausea, diarrhoea, flushing and itchness…
The current study is designed to evaluate the safety and efficacy of combination therapy with pembrolizumab + lenvatinib versus pembrolizumab + placebo in cisplatin-ineligible participants whose tumors express PD-L1 (CPS >=10) and…
Primary objective: The primary objective of this study is to investigate if taking methenamine hippurate reduce the need for antibiotic usage due to recurrent UTI (measured as the number of courses of antibiotics).Secondary objectives:to investigate…
The primary aim of the study is to improve microvascular endothelial health after 3 months expressed by the Microvascular Healt Index, using a non-invasive imaging technique, upon two different dietary interventions compared to the placebo. The…
Primary: * To assess the change baseline in 24-hr proteinuria with dapagliflozin for six weeks relative to placebo treatment in patients with non-diabetic kidney disease and proteinuria > 500 mg/day on stable ACEi or ARB treatment. Secondary…
Co-primary (tested in parallel for non-inferiority):- To compare daprodustat to rhEPO for CV safety (non-inferiority)- To compare daprodustat to rhEPO for Hgb efficacy(non-inferiority)
Co-primary (tested in parallel for non-inferiority):-To compare daprodustat to darbepoetin alfa for CV safety (non-inferiority)-To compare daprodustat to darbepoetin alfa for Hgb efficacy(non-inferiority)
To assess the effects of intradialytic exercise and protein ingestion on amino acid loss into the dialysate and plasma total amino acid concentrations.
Primary Objective:* To demonstrate the safety of intravenous (i.v.) iodinated iso-osmolar iodixanol (Visipaque* Injection 320 mgI/mL) usage in contrast-enhanced computed tomography (CECT) for CKD stage III/IV patients by evaluating the incidence of…